United Therapeutics officer plans $4.97M share sale
The reported prior sales each involved 8,300 UTHR common shares and spanned August 6, 2026, through October 15, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corporation (UTHR) officer Paul Mahon reports a planned sale of 8,300 common shares on November 5, 2026, with an aggregate market value of $4,968,932.78. Morgan Stanley Smith Barney LLC is listed as the broker. The securities are shown as acquired from the issuer through a stock option exercise for cash on November 5, 2026. Mahon also reported six prior sales of 8,300 shares each between August 6, 2026, and October 15, 2026.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.